Boston Scientific aims to market stent to diabetics
519920
Boston Scientific Corp. , of Natick, is seeking to market its Taxus heart stent to diabetics in the United States, who make up one-third of all stent patients. Taxus shows signs of being at least as effective and safe in diabetics as the rival Cypher stent, made by Johnson &amp; Johnson, Donald Baim, chief scientific officer at Boston ...
717588
Indianapolis-based Guidant Corp., which co-promotes Johnson &amp; Johnson&#39;s Cypher drug-coated heart stent, says the device&#39;s market share has risen by as much as half, helped by Boston Scientific Corp.
347470
VIENNA - Boston Scientific Corp. yesterday said its Taxus Liberte drug-coated stent has shown positive one-year safety data in over 7,000 patients.
614727
The FDA is about to make it harder for drug-eluting stents to win its approval.
700160
Boston Scientific Corp. shipped millions of dollars worth of coronary stents in fall 1998 even after company officials learned that the medical devices had
191741
Boston Scientific Corp.  posted a lower-than-expected quarterly profit on Friday as sales of its flagship drug-eluting heart stent fell by 32 percent.
589861
Swiss drug giant Novartis SA said yesterday it is spending $4 million to fund scientists performing diabetes research at Harvard University, the Massachusetts Institute of Technology, and the Broad Institute, and will make the findings public for other scientists to use.
524340
NEW YORK, September 1 (New Ratings) - Boston Scientificâs (BSX.NYS) share price rose more than 6% on the news of market share regains by Taxus, the company&#39;s drug-coated stent.
576953
Boston Scientific Corp. has introduced the Taxus Liberte coronary stent, the second generation of its market-leading product, to 18 countries in Asia, Africa, and South America. The Natick company expects to launch the product in Europe this year. In the United States, the product is in the clinical-trial phase of regulatory approval.
93936
The concerns that have been raised about the safety of drug-eluting stents at a major cardiology conference shouldn't mean it's time to go back to older treatments, the chief medical and scientific officer of Natick medical technology company Boston Scientific Corp. said yesterday.
445058
Bloomington (Star report) --Boston Scientific Corp. has obtained exclusive rights to sell the most popular coating on heart stents, taking over the share previously held by Cook Inc.
63981
GAITHERSBURG, Maryland  - A U.S. advisory panel heard evidence on Thursday about risks of drug-coated stents, the tiny mesh tubes used to prop open arteries in millions of heart patients.
586348
As part of a federal inquiry into drug and medical-device marketing, Boston Scientific Corp. was asked by Congress last week to submit to investigators internal documents, marketing plans, and clinical data related to its top-selling product, the Taxus drug-coated stent.
290938
Boston Scientific Corp. BSX.N on   Thursday said an internal analysis confirmed an increased risk   of blood clots with its drug-coated device used to keep   previously clogged arteries open.
43609
Boston Scientific Corp.  posted lower-than-expected quarterly profit on Friday as sales of its flagship drug-eluting heart stents fell by 32 percent.
155100
Standard &amp; Poor's raised its outlook on Boston Scientific Corp. to positive from stable, citing its recovery of market share for its drug-coated Taxus cardiac stent after recalls that began in July. The debt rating agency said the upgrade reflects the Natick company's &quot;surprisingly rapid recovery&quot; of market share for Taxus, and its diverse product line. Last week, Boston Scientific ...
333292
Last Thursday, the day the Food and Drug Administration launched a two-day advisory panel on the risks of drug-coated stents, doctors across the country found an e-mail on their computers from stent maker Johnson &amp; Johnson, inviting them to join a conference call about stent safety.